RxDoctor Payments DataLook up a doctor →

Frankie Rholdon, MD

Dermatology · Lafayette, LANPI 1528252681

Payments from drug & device makers

$227,200in general payments, 2019–2025

Across 793 payments — averaging $286.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$75K
  • Arcutis Biotherapeutics, Inc.$67K
  • Galderma Laboratories, L.p.$30K
  • Novartis$29K
  • Pfizer$9K
  • Kowa Pharmaceuticals America, Inc.$6K
  • plus $11K from 29 others

What the payments were for

  • Consulting fees$48,50521%
  • Speaking & faculty fees$124,53055%
  • Travel & lodging$34,49315%
  • Food & beverage$19,2158%
  • Education$4570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$227,200 in reported general payments places this provider in the 90th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$472,895
Medicare patients
898
Services billed
6,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab22$159,809
Cosentyx Unoready PenSecukinumab11$103,059
Cosentyx (2 Syringes)Secukinumab13$87,979
OtezlaApremilast11$51,456
Dupixent SyringeDupilumab11$39,432
Clobetasol Propionate91$3,981
Fluocinonide92$3,839
Ketoconazole285$3,794
Doxycycline Hyclate126$3,242
Hydroxychloroquine Sulfate59$2,579
Desonide32$1,379
ValacyclovirValacyclovir Hcl90$1,218
Minoxidil150$1,189
Triamcinolone Acetonide92$1,166
Betamethasone Dipropionate24$1,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$29,224$87,97913 claims
AmgenOtezla$413$51,45611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 189 dermatology providers in Louisiana.

Other dermatology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →